All Outputs (3)

Hyperthyroidism, and bone mineral density : dissecting the causal association with Mendelian randomization analysis (2020)
Journal Article
Deshmukh, H., Papageorgiou, M., Aye, M., England, J., Abdalla, M., & Sathyapalan, T. (in press). Hyperthyroidism, and bone mineral density : dissecting the causal association with Mendelian randomization analysis. Clinical Endocrinology, https://doi.org/10.1111/cen.14330

Introduction Untreated hyperthyroidism is associated with accelerated bone turnover, low bone mineral density (BMD) and increased susceptibility to fragility fractures. Although treatment appears to improve or even reverse some of these adverse skel... Read More about Hyperthyroidism, and bone mineral density : dissecting the causal association with Mendelian randomization analysis.

A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform (2019)
Journal Article
Riley, A., Green, V., Cheah, R., McKenzie, G., Karsai, L., England, J., & Greenman, J. (2019). A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform. BMC Cancer, 19(1), Article 259. https://doi.org/10.1186/s12885-019-5465-z

© 2019 The Author(s). Background: Though the management of malignancies has improved vastly in recent years, many treatment options lack the desired efficacy and fail to adequately augment patient morbidity and mortality. It is increasingly clear tha... Read More about A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform.

A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform (2019)
Journal Article
Riley, A., Green, V., Cheah, R., McKenzie, G., Karsai, L., England, J., & Greenman, J. (2019). A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform. BMC Cancer, 19(1), Article 259. https://doi.org/10.1186/s12885-019-5465-z

Background Though the management of malignancies has improved vastly in recent years, many treatment options lack the desired efficacy and fail to adequately augment patient morbidity and mortality. It is increasingly clear that patient response to... Read More about A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform.